Affordable Access

deepdyve-link
Publisher Website

Acute Graft-versus-Host Disease: Emerging Insights and Updates into Detection, Prevention, and Treatment.

Authors
  • DiMaggio, Elizabeth1
  • 1 Department of Pharmacy, Moffitt Cancer Center, Tampa, Florida, USA.
Type
Published Article
Journal
Pharmacotherapy
Publication Date
Aug 01, 2020
Volume
40
Issue
8
Pages
788–807
Identifiers
DOI: 10.1002/phar.2436
PMID: 32530080
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Acute graft-versus-host disease remains a devastating complication following hematopoietic cell transplantation, resulting in increased morbidity and mortality. Vast research efforts continue to refine or develop new means of prediction, assessment, prevention, and treatment of this syndrome. Recent updates in acute graft-versus-host disease include more definitive guidance and definitions for its grading and diagnosis. Biomarker use is being incorporated into early stages following hematopoietic cell transplantation to aid in the detection and prediction of long-term outcomes. New preventive strategies under investigation include the use of vedolizumab or tocilizumab as upfront prophylaxis. Finally, although steroids remain the backbone of therapy once treatment is warranted, the efficacy of several agents including vedolizumab, tocilizumab, ruxolitinib, and α1 antitrypsin are being evaluated as potential therapeutic options. © 2020 Pharmacotherapy Publications, Inc.

Report this publication

Statistics

Seen <100 times